Inovio Pharmaceuticals (INO) Invested Capital (2010 - 2023)

Inovio Pharmaceuticals has reported Invested Capital for 14 years, with the latest figure at $16.8 million in Q4 2023.

• Quarterly Invested Capital changed N/A year-over-year to $16.8 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $16.8 million (down 66.18% YoY) and the FY2023 annual result came in at $16.8 million, changed N/A from the prior year.
• Invested Capital advanced to $16.8 million in Q4 2023 per INO's latest filing, from $16.5 million in the prior quarter.
• Over five years, Invested Capital peaked at $16.8 million in Q4 2023 and troughed at $263456.0 in Q1 2020.
• A 5-year average of $4.2 million and a median of $794928.0 in 2020 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2020 and 2023: Invested Capital plunged 79.97% in 2020, then jumped 1148.11% in 2023.
• Over 5 years, Invested Capital stood at $729729.0 in 2019, then declined by 11.89% to $642969.0 in 2020, then declined by 14.77% to $548032.0 in 2021, then surged by 198.12% to $1.6 million in 2022, then soared by 926.49% to $16.8 million in 2023.
• According to Business Quant data, Invested Capital over the past three periods registered $16.8 million, $16.5 million, and $16.7 million for Q4 2023, Q3 2023, and Q2 2023 respectively.